HLS Therapeutics (HLS.TO) Stock Price
HLS Therapeutics Price
HLS Therapeutics (HLS.TO) Stock | ISIN CA40390B1094 | WKN A2JGH0. The current HLS Therapeutics stock price is 3.42 USD (2026). Revenue is 62.22 M USD. Net income is -7.07 M USD. The P/E ratio is -15.41. Market capitalization is 109.03 M USD. HLS Therapeutics operates in the Health sector.
HLS Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of HLS Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how HLS Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing HLS Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | HLS Therapeutics Price |
|---|
HLS Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
HLS Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| DIVIDEND (USD)DIV. (USD) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|
| 63 | 56 | 55 | 62 | 69 | 66 | 71 | 75 |
| 3.28 | -11.11 | -1.79 | 12.73 | 11.29 | -4.35 | 7.58 | 5.63 |
| 87.3 | 83.93 | 85.45 | 75.81 | 68.12 | 71.21 | 66.2 | 62.67 |
| 55 | 47 | 47 | 47 | 47 | 47 | 47 | 47 |
| -27 | -19 | -12 | -7 | -1 | 4 | 10 | 16 |
| 17.39 | -29.63 | -36.84 | -41.67 | -85.71 | -500 | 150 | 60 |
| 0.2 | - | - | - | - | - | - | - |
| – | – | – | – | – | – | – | – |
| 32.26 | 31.84 | 31.84 | 31.84 | 31.84 | 31.84 | 31.84 | 31.84 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales HLS Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue HLS Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare HLS Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares HLS Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against HLS Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
HLS Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
HLS Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
HLS Therapeutics business model & stock analysis
HLS Therapeutics SWOT Analysis
Strengths
1. Strong market presence: HLS Therapeutics Inc has established a strong presence in the pharmaceutical industry, allowing them to leverage their brand and reputation.
2. Diversified product portfolio: The company offers a range of pharmaceutical products, providing them with multiple revenue streams and reducing dependence on a single product.
3. Experienced management team: HLS Therapeutics Inc is led by a highly experienced management team with deep industry knowledge and expertise.
Weaknesses
1. Limited geographic presence: The company primarily operates in specific regions, limiting its potential market reach and growth opportunities in new markets.
2. Dependence on external suppliers: HLS Therapeutics Inc relies on external suppliers for the procurement of raw materials, which exposes them to supply chain risks and potential disruptions.
3. Relatively small market share: Compared to some of its competitors, HLS Therapeutics Inc holds a relatively smaller market share, which may pose challenges in terms of market penetration and competition.
Opportunities
1. Emerging markets: Expanding into emerging markets with a growing elderly population presents HLS Therapeutics Inc with opportunities to tap into new customer segments and increase sales.
2. Strategic partnerships and acquisitions: Collaborating with strategic partners or acquiring smaller pharmaceutical companies can provide HLS Therapeutics Inc with access to new technologies, products, and markets.
3. R&D investments: Investing in research and development can enable HLS Therapeutics Inc to develop innovative drugs and treatments, potentially leading to a competitive advantage.
Threats
1. Regulatory challenges: Increasing regulations in the pharmaceutical industry may impose additional compliance requirements and impact the company's operations and profitability.
2. Intense competition: HLS Therapeutics Inc operates in a highly competitive market with numerous established pharmaceutical companies, posing threats to market share and pricing pressures.
3. Economic uncertainties: Fluctuations in the economy, including changes in healthcare policies and reimbursement systems, can influence the demand for pharmaceutical products and impact the company's financial performance.
HLS Therapeutics Eulerpool Fair Value
HLS Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
HLS Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
HLS Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
HLS Therapeutics Dividend History
27 years of dividend payments
HLS Therapeutics dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
HLS Therapeutics Earnings Estimates
HLS Therapeutics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/9/2024 | -0.08USD | 16.46 MUSD | 2024 Q1 |
| 3/14/2024 | -0.1USD | 16.63 MUSD | 2023 Q4 |
| 8/9/2023 | -0.1USD | 25.31 MUSD | 2023 Q2 |
| 5/3/2023 | -0.13USD | 22.67 MUSD | 2023 Q1 |
| 3/15/2023 | -0.07USD | 17.95 MUSD | 2022 Q4 |
| 11/10/2022 | -0.13USD | 16.83 MUSD | 2022 Q3 |
| 8/11/2022 | -0.08USD | 16.83 MUSD | 2022 Q2 |
| 5/5/2022 | -0.1USD | 15.82 MUSD | 2022 Q1 |
| 3/17/2022 | -0.1USD | 16.98 MUSD | 2021 Q4 |
| 11/4/2021 | -0.11USD | 16.13 MUSD | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the HLS Therapeutics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
HLS Therapeutics shareholder structure
| % | Name |
|---|---|
19.99743% | |
18.73409% | |
5.54311% | |
0.54053% | |
0.44374% | |
0.09837% | |
0.06336% | |
0.03926% | |
0.02513% | |
0.01291% |
HLS Therapeutics Executives and Management Board
Mr. Craig Millian
(57)Chief Executive Officer, Director · since 2023
Mr. Brian Walsh
(47)Chief Commercial Officer
Mr. John Hanna
(60)Chief Financial Officer, Director · since 2023
Mr. Ryan Lennox
(44)Senior Vice President - Legal, HR and Compliance, Corporate Secretary
Mr. Jason Gross
(60)Vice President - Scientific Affairs
HLS Therapeutics Supply Chain
Frequently asked questions about HLS Therapeutics
The business model of HLS Therapeutics Inc focuses on commercializing and acquiring innovative healthcare products and technologies. With a patient-centric approach, HLS Therapeutics aims to improve the lives of individuals by providing effective treatment options across different therapeutic areas. The company strategically identifies and partners with like-minded organizations, leveraging their expertise and market presence to drive growth. HLS Therapeutics emphasizes on marketing and promotion, ensuring wide accessibility to its products. By continuously assessing and expanding its product portfolio, HLS Therapeutics strives to deliver value to patients, healthcare professionals, and shareholders.
HLS Therapeutics stock
HLS Therapeutics Peer Group
HLS Therapeutics Ticker
HLS Therapeutics FIGI
All fundamentals and in-depth analysis of HLS Therapeutics
Our stock analysis for HLS Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLS Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.